{"id":3825,"date":"2026-11-17T07:30:49","date_gmt":"2026-11-17T13:30:49","guid":{"rendered":"https:\/\/www.molllawgroup.com\/blog\/?p=3825"},"modified":"2026-11-07T20:59:22","modified_gmt":"2026-11-08T02:59:22","slug":"forty-people-sue-over-dupixent","status":"publish","type":"post","link":"https:\/\/www.molllawgroup.com\/blog\/forty-people-sue-over-dupixent\/","title":{"rendered":"Forty People Sue Over Dupixent"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"alignleft wp-image-3826 size-full\" src=\"https:\/\/www.molllawgroup.com\/blog\/wp-content\/uploads\/2026\/11\/fernandozhiminaicela-treatment-40994322-scaled-e1794106487923.jpg\" alt=\"fernandozhiminaicela-treatment-40994322-scaled-e1794106487923\" width=\"599\" height=\"400\" \/>Forty people have filed lawsuits about Dupixent, which patients use for eczema but which has been linked to cutaneous T-cell lymphoma. The first person to <a href=\"https:\/\/www.wkrn.com\/news\/local-news\/nashville\/antioch-womans-lawsuit-gains-momentum-over-dupixent-after-moms-2024-death\/\">file suit<\/a> was a woman who lost her mother in 2024; her mom had developed medical problems soon after her first injection, according to the plaintiff. \u00a0If you or a loved one developed T-cell lymphoma after using Dupixent, you should call the seasoned Chicago-based product liability lawyers of Moll Law Group to see whether you have a viable claim. Billions have been recovered in cases with which we\u2019ve been involved.<\/p>\n<p><strong>Consult Moll Law Group About Your Claim<\/strong><\/p>\n<p>The litigation over Dupixent has built. There are now 40 federal cases that have been consolidated. More than 12 cases have been brought in state court. The plaintiff\u2019s attorney has explained that sometimes T-cell lymphoma and eczema are confused by doctors. When a patient comes in, the doctor may diagnose eczema when the actual cause of the symptoms is T-cell lymphoma and prescribe Dupixent. Unfortunately, Dupixent can accelerate the progression of T-cell lymphoma.<\/p>\n<p>The plaintiff\u2019s attorney wants drug manufacturers to warn doctors to ensure that the patients don\u2019t have T-cell lymphoma, which may be dormant prior to the taking of Dupixent.<\/p>\n<p> <a href=\"https:\/\/www.molllawgroup.com\/blog\/forty-people-sue-over-dupixent\/#more-3825\" class=\"more-link\">Continue reading \u2192<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Forty people have filed lawsuits about Dupixent, which patients use for eczema but which has been linked to cutaneous T-cell lymphoma. The first person to file suit was a woman who lost her mother in 2024; her mom had developed medical problems soon after her first injection, according to the plaintiff. \u00a0If you or a [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":3826,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,3],"tags":[],"class_list":["post-3825","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharmaceuticals","category-product-liability"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Forty People Sue Over Dupixent &#8212; Illinois Injury and Mass Tort Lawyer Blog &#8212; November 17, 2026<\/title>\n<meta name=\"description\" content=\"Forty people have filed lawsuits about Dupixent, which patients use for eczema but which has been linked to cutaneous T-cell lymphoma. The first person to &#8212; November 17, 2026\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.molllawgroup.com\/blog\/forty-people-sue-over-dupixent\/\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Forty People Sue Over Dupixent &#8212; Illinois Injury and Mass Tort Lawyer Blog &#8212; November 17, 2026\" \/>\n<meta name=\"twitter:description\" content=\"Forty people have filed lawsuits about Dupixent, which patients use for eczema but which has been linked to cutaneous T-cell lymphoma. The first person to &#8212; November 17, 2026\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/www.molllawgroup.com\/blog\/wp-content\/uploads\/2026\/11\/fernandozhiminaicela-treatment-40994322-scaled-e1794106487923.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Moll Law Group\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Forty People Sue Over Dupixent &#8212; Illinois Injury and Mass Tort Lawyer Blog &#8212; November 17, 2026","description":"Forty people have filed lawsuits about Dupixent, which patients use for eczema but which has been linked to cutaneous T-cell lymphoma. The first person to &#8212; November 17, 2026","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.molllawgroup.com\/blog\/forty-people-sue-over-dupixent\/","twitter_card":"summary_large_image","twitter_title":"Forty People Sue Over Dupixent &#8212; Illinois Injury and Mass Tort Lawyer Blog &#8212; November 17, 2026","twitter_description":"Forty people have filed lawsuits about Dupixent, which patients use for eczema but which has been linked to cutaneous T-cell lymphoma. The first person to &#8212; November 17, 2026","twitter_image":"https:\/\/www.molllawgroup.com\/blog\/wp-content\/uploads\/2026\/11\/fernandozhiminaicela-treatment-40994322-scaled-e1794106487923.jpg","twitter_misc":{"Written by":"Moll Law Group","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.molllawgroup.com\/blog\/forty-people-sue-over-dupixent\/#article","isPartOf":{"@id":"https:\/\/www.molllawgroup.com\/blog\/forty-people-sue-over-dupixent\/"},"author":{"name":"Moll Law Group","@id":"https:\/\/www.molllawgroup.com\/blog\/#\/schema\/person\/53d2eb37d5d0cdb46ac61abacf05ce90"},"headline":"Forty People Sue Over Dupixent","datePublished":"2026-11-17T13:30:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.molllawgroup.com\/blog\/forty-people-sue-over-dupixent\/"},"wordCount":535,"image":{"@id":"https:\/\/www.molllawgroup.com\/blog\/forty-people-sue-over-dupixent\/#primaryimage"},"thumbnailUrl":"https:\/\/www.molllawgroup.com\/blog\/wp-content\/uploads\/2026\/11\/fernandozhiminaicela-treatment-40994322-scaled-e1794106487923.jpg","articleSection":["Pharmaceuticals","Product Liability"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.molllawgroup.com\/blog\/forty-people-sue-over-dupixent\/","url":"https:\/\/www.molllawgroup.com\/blog\/forty-people-sue-over-dupixent\/","name":"Forty People Sue Over Dupixent &#8212; Illinois Injury and Mass Tort Lawyer Blog &#8212; November 17, 2026","isPartOf":{"@id":"https:\/\/www.molllawgroup.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.molllawgroup.com\/blog\/forty-people-sue-over-dupixent\/#primaryimage"},"image":{"@id":"https:\/\/www.molllawgroup.com\/blog\/forty-people-sue-over-dupixent\/#primaryimage"},"thumbnailUrl":"https:\/\/www.molllawgroup.com\/blog\/wp-content\/uploads\/2026\/11\/fernandozhiminaicela-treatment-40994322-scaled-e1794106487923.jpg","datePublished":"2026-11-17T13:30:49+00:00","author":{"@id":"https:\/\/www.molllawgroup.com\/blog\/#\/schema\/person\/53d2eb37d5d0cdb46ac61abacf05ce90"},"description":"Forty people have filed lawsuits about Dupixent, which patients use for eczema but which has been linked to cutaneous T-cell lymphoma. The first person to &#8212; November 17, 2026","breadcrumb":{"@id":"https:\/\/www.molllawgroup.com\/blog\/forty-people-sue-over-dupixent\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.molllawgroup.com\/blog\/forty-people-sue-over-dupixent\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.molllawgroup.com\/blog\/forty-people-sue-over-dupixent\/#primaryimage","url":"https:\/\/www.molllawgroup.com\/blog\/wp-content\/uploads\/2026\/11\/fernandozhiminaicela-treatment-40994322-scaled-e1794106487923.jpg","contentUrl":"https:\/\/www.molllawgroup.com\/blog\/wp-content\/uploads\/2026\/11\/fernandozhiminaicela-treatment-40994322-scaled-e1794106487923.jpg","width":599,"height":400},{"@type":"BreadcrumbList","@id":"https:\/\/www.molllawgroup.com\/blog\/forty-people-sue-over-dupixent\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.molllawgroup.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Forty People Sue Over Dupixent"}]},{"@type":"WebSite","@id":"https:\/\/www.molllawgroup.com\/blog\/#website","url":"https:\/\/www.molllawgroup.com\/blog\/","name":"Illinois Injury and Mass Tort Lawyer Blog","description":"Published by Illinois Injury and Mass Tort Attorney \u2014 Moll Law Group","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.molllawgroup.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.molllawgroup.com\/blog\/#\/schema\/person\/53d2eb37d5d0cdb46ac61abacf05ce90","name":"Moll Law Group","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/0febdc96ea554e620e775358f9d7e4fc56616188dfd2bb21b18c2fed4bd185a0?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/0febdc96ea554e620e775358f9d7e4fc56616188dfd2bb21b18c2fed4bd185a0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0febdc96ea554e620e775358f9d7e4fc56616188dfd2bb21b18c2fed4bd185a0?s=96&d=mm&r=g","caption":"Moll Law Group"}}]}},"jetpack_featured_media_url":"https:\/\/www.molllawgroup.com\/blog\/wp-content\/uploads\/2026\/11\/fernandozhiminaicela-treatment-40994322-scaled-e1794106487923.jpg","_links":{"self":[{"href":"https:\/\/www.molllawgroup.com\/blog\/wp-json\/wp\/v2\/posts\/3825","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.molllawgroup.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.molllawgroup.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.molllawgroup.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.molllawgroup.com\/blog\/wp-json\/wp\/v2\/comments?post=3825"}],"version-history":[{"count":1,"href":"https:\/\/www.molllawgroup.com\/blog\/wp-json\/wp\/v2\/posts\/3825\/revisions"}],"predecessor-version":[{"id":3827,"href":"https:\/\/www.molllawgroup.com\/blog\/wp-json\/wp\/v2\/posts\/3825\/revisions\/3827"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.molllawgroup.com\/blog\/wp-json\/wp\/v2\/media\/3826"}],"wp:attachment":[{"href":"https:\/\/www.molllawgroup.com\/blog\/wp-json\/wp\/v2\/media?parent=3825"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.molllawgroup.com\/blog\/wp-json\/wp\/v2\/categories?post=3825"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.molllawgroup.com\/blog\/wp-json\/wp\/v2\/tags?post=3825"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}